Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344132 | 1.00 | POLQ (0.43) | POLQKDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL2827522 | 0.82 | ALDH1A1 (0.40) | KDM4EALDH1A1IDO1MAOB | |
| SCHEMBL2827524 | 0.82 | ALDH1A1 (0.40) | KDM4EALDH1A1IDO1MAOB | |
| SCHEMBL5342416 | 0.81 | CTBP2 (0.40) | KDM4EALDH1A1MAOB | |
| SCHEMBL5342412 | 0.81 | CTBP2 (0.40) | KDM4EALDH1A1MAOB | |
| SCHEMBL5352600 | 0.79 | ALDH1A1 (0.40) | KDM4EALDH1A1MAOBMAOA | |
| SCHEMBL5352596 | 0.79 | ALDH1A1 (0.40) | KDM4EALDH1A1MAOBMAOA | |
| SCHEMBL29195791 | 0.78 | POLQ (0.49) | POLQKDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL5337175 | 0.74 | FFAR1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5337171 | 0.74 | FFAR1 (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | CARROLL WILLIAM A | 2007-10-04 | — | — | US | disclosed |
| US-7241776-B2 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBVIE INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | P2RX2, P2RX1, P2RX7 | POLQ 4344/4885KDM4E 3687/4885ALDH1A1 3848/4885 |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | P2RX2, P2RX1, P2RX7 | POLQ 4344/4885KDM4E 3687/4885ALDH1A1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.